Updated:
NuChem Sciences Inc.
NuChem Sciences Inc. is an asset manager based in Saint-Laurent; the Altss profile covers its classification, headquarters, registration, AUM band, and key...
Overview
Sygnature Discovery is a world-leading integrated drug discovery CRO based in the UK and Canada with headquarters in Nottingham (UK).
General information
Firm type
Asset Manager
Location
Region
North America
Country
Canada
City
Saint-Laurent
Corporate office
201-2350 Cohen, Saint-Laurent, Quebec H4R 2N6, Canada
Additional offices
Nottingham, UK · Alderley Park, UK · Glasgow, UK · Tytherington, UK · Lévis, Canada
Frequently asked questions
Does NuChem Sciences invest in drug development or only provide services?
NuChem Sciences provides contract research services only. Sygnature Discovery states it has no internal drug pipeline, meaning the firm does not invest its own capital in developing drugs. Instead, it charges fees for preclinical discovery services across multiple therapeutic areas.
What services does NuChem Sciences offer?
NuChem Sciences (via Sygnature Discovery) offers integrated drug discovery services including computer-aided drug design, protein science, bioscience, chemistry, drug metabolism and pharmacokinetics, in vivo pharmacology, and formulation development. The firm claims expertise across oncology, neuroscience, anti-infectives, and metabolic, inflammatory, fibrotic, and respiratory diseases.
Where are NuChem Sciences' offices located?
NuChem Sciences maintains two Canadian offices: one in Saint-Laurent, Quebec (201-2350 Cohen) and one in Lévis, Quebec (480 rue Perreault). The parent company Sygnature Discovery has UK offices in Nottingham (HQ), Alderley Park, Glasgow, and Tytherington.
Profile maintained by Altss. Updated: . To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on asset managers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: